Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test.
Cannabinoids affect various behavioral processes, including emotion, learning and memory, which may be specifically regulated through the CB1 receptors. The exact role CB1 receptors play in anxiety remains unclear. Both genetic and pharmacological blockade of CB1 receptors have produced inconsistent effects on anxiety. However, these studies examined passive avoidance as an index of anxiety. In the present study, both active and passive avoidance were examined using the shock-probe burying test while CB1 receptors were blocked genetically or pharmacologically. In the shock-probe burying test, anxiety is reflected by increased burying (increased active avoidance) and increased freezing (increased passive avoidance). In addition, probe-contacts may reflect cognitive performance and/or passive avoidance. As there have been few studies examining mouse behavior in the shock-probe burying test, experiment 1 was designed to pharmacologically validate this model in mice. Our results indicated that administration (i.p.) of chlordiazepoxide (4 mg/kg) or FG7412 (5 mg/kg) decreased and increased burying behavior, respectively, without affecting freezing or the number of probe contacts. Experiments 2 and 3 showed that both CB1 knockout mice and mice injected (i.p.) with 3 or 10 mg/kg, but not 1 mg/kg, of the CB1 receptor antagonist SR141716A had lower burying scores, fewer contacts with the probe and similar freezing times compared with wild-type mice and mice injected with vehicle (experiments 2 and 3). Collectively, these results suggest that CB1 receptor blockade reduces some, but not all, aspects of anxiety. The decrease in probe contacts induced by CB1 receptor blockade may be due to enhanced cognition.
Eli Lilly and Company, Lilly Corporate Center, Neuroscience Discovery Research, Indianapolis, IN, 46285-0510, USA.
Aldemar
A
Degroot
George G
GG
Nomikos
D000818:Animals; D001007:Anxiety / Q000235:genetics* / Q000378:metabolism / Q000523:psychology; D002243:Carbolines / Q000494:pharmacology; D002707:Chlordiazepoxide / Q000494:pharmacology; D004597:Electroshock / Q000379:methods*; D017353:Gene Deletion; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics*; D000077285:Rimonabant
D002243:Carbolines; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C035874:FG 7142; D002707:Chlordiazepoxide; D000077285:Rimonabant